AI-generated from publicly available materials.The pharmaceutical industry is increasingly adopting AI technologies, particularly through the development of digital clones, which are seen as more accurate alternatives to traditional digital twins.
In a recent discussion, Hamish Brocklebank, founder of Brox.AI, emphasized the evolving landscape of AI applications in pharma. While digital twins have been a hot topic, Brocklebank's company has shifted to using the term "digital clones" to better reflect their approach. This change highlights a significant distinction in methodology and application, particularly in enhancing research accuracy.
Brocklebank outlined three main categories of AI applications in the industry. The first involves traditional research methods that do not utilize digital twins at all. The second category pertains to the more common interpretation of digital twins, which involves generating synthetic data to simulate patient or doctor behavior. This is where many competitors focus their efforts. In contrast, Brox.AI's approach emphasizes creating one-to-one clones of real individuals, prioritizing precision over convenience.
The rapid growth of AI technologies in pharma reflects the industry's urgent need for speed and accuracy in research and development. As traditional methods struggle to keep pace with the demands for quicker, data-driven decisions, the shift towards digital clones may represent a pivotal advancement in how pharmaceutical research is conducted.